4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1,2,4)triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies

US7485639B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Hans-Michael Eggenweiler · Darmstadt, DE
• Michael Wolf · Darmstadt, DE
• Norbert Beier · Reinheim, DE
• Joachim Leibrock · Gauting, DE
• Pierre Schelling · Mühltal, DE
• Michael Gassen · Munich, DE
• Thomas Ehring · Remscheid, DE

Key dates

• Filing date: Jun 19, 2002
• Grant date: Feb 3, 2009
• Expiry date: Feb 29, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R1, R2, A and R5 are as defined in Claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and AIDS, furthermore for inhibiting the formation of TNFα.